SCHEMBL20522273

SCHEMBL20522273

COc1ccc(-c2c(C)cccc2N)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 4/20 0.53
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 3/20 0.48
CYP3A4 P08684 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
TSHR P16473 1/20 0.48
QPCT Q16769 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
PDE4A P27815 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
DHFR P00374 1/20 0.43
ACHE P22303 1/20 0.42
ADRA2B P18089 1/20 0.42
PTGS1 P23219 1/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11292098 0.89 KDM4E (0.54) ALDH1A1KDM4ESMN1; SMN2HSD17B10CYP3A4
SCHEMBL11282919 0.86 KDM4E (0.51) ALDH1A1KDM4ESMN1; SMN2HSD17B10TSHR
SCHEMBL20522397 0.83 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2HSD17B10CYP3A4
SCHEMBL2936122 0.83 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2HSD17B10CYP3A4
SCHEMBL31667846 0.82 ALDH1A1 (0.68) ALDH1A1KDM4ESMN1; SMN2HSD17B10CYP3A4
SCHEMBL2934128 0.78 PTGS1 (0.41) ALDH1A1KDM4EHSD17B10CYP3A4TDP1
SCHEMBL9679255 0.77 SYK (0.48) ALDH1A1KDM4ESMN1; SMN2CYP3A4TDP1
SCHEMBL30610429 0.77 SYK (0.48) ALDH1A1KDM4ESMN1; SMN2CYP3A4TDP1
SCHEMBL5151525 0.76 ALDH1A1 (0.55) ALDH1A1KDM4ESMN1; SMN2HSD17B10CA1
SCHEMBL30610422 0.75 KIT (0.61) ALDH1A1KDM4ESMN1; SMN2HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 ALDH1A1 1183/4885KDM4E 1773/4885SMN1; SMN2 3039/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1681/4885KDM4E 1119/4885SMN1; SMN2 4713/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS ALDH1A1 1490/4885KDM4E 1078/4885SMN1; SMN2 4705/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 ALDH1A1 1415/4885KDM4E 1254/4885SMN1; SMN2 4094/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ALDH1A1 1184/4885KDM4E 1160/4885SMN1; SMN2 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.